These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 14984280)

  • 1. Cost data assessment in multinational economic evaluations: some theory and review of published studies.
    Halliday RG; Darba J
    Appl Health Econ Health Policy; 2003; 2(3):149-55. PubMed ID: 14984280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities.
    Wordsworth S; Ludbrook A
    Health Econ; 2005 Jan; 14(1):93-9. PubMed ID: 15386663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal search strategies for detecting cost and economic studies in EMBASE.
    McKinlay RJ; Wilczynski NL; Haynes RB;
    BMC Health Serv Res; 2006 Jun; 6():67. PubMed ID: 16756662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of transparency of cost estimates in economic evaluations of patient safety programmes.
    Fukuda H; Imanaka Y
    J Eval Clin Pract; 2009 Jun; 15(3):451-9. PubMed ID: 19366392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
    Nicholson A; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Schramm W; van Hout BA; Willan AR; Feldman BM
    Haemophilia; 2008 Jan; 14(1):127-32. PubMed ID: 18005148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?
    Glick HA; Orzol SM; Tooley JF; Polsky D; Mauskopf JO
    Health Econ; 2003 Jul; 12(7):517-27. PubMed ID: 12825205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of alternative staff time data collection methods on drug treatment service cost estimates.
    Zarkin GA; Dunlap LJ; Wedehase B; Cowell AJ
    Eval Program Plann; 2008 Nov; 31(4):427-35. PubMed ID: 18640722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calculation of workers' health care costs].
    Rydlewska-Liszkowska I
    Med Pr; 2006; 57(6):567-71. PubMed ID: 17533995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multinational assessment of some operational costs of teletherapy.
    Van Der Giessen PH; Alert J; Badri C; Bistrovic M; Deshpande D; Kardamakis D; Van Der Merwe D; Da Motta N; Pinillos L; Sajjad R; Tian Y; Levin V
    Radiother Oncol; 2004 Jun; 71(3):347-55. PubMed ID: 15172152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using multilevel models for assessing the variability of multinational resource use and cost data.
    Grieve R; Nixon R; Thompson SG; Normand C
    Health Econ; 2005 Feb; 14(2):185-96. PubMed ID: 15386660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation].
    Krauth C; Hessel F; Hansmeier T; Wasem J; Seitz R; Schweikert B
    Gesundheitswesen; 2005 Oct; 67(10):736-46. PubMed ID: 16235143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do we evaluate the economics of health care?
    Kumar S; Williams AC; Sandy JR
    Eur J Orthod; 2006 Dec; 28(6):513-9. PubMed ID: 17035484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic cost analysis in cancer management and its relevance today.
    Sharma K; Das S; Mukhopadhyay A; Rath GK; Mohanti BK
    Indian J Cancer; 2009; 46(3):184-9. PubMed ID: 19574668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.